Long-term Parkinson's disease - Time for optimism

被引:4
|
作者
Yust-Katz, Shlomit [1 ,2 ]
Sthneer, Sonia [1 ,2 ]
Melamed, Eldad [1 ,2 ]
Djaldetti, Ruth [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Neurol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
Parkinson's disease; long term; levodopa; Hoehn and Yahr stage;
D O I
10.1016/j.biopha.2007.12.014
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Data on the natural long-term course of Parkinson's disease (PD) remain sparse. The aim of this study was to describe the evolution of the functional disability and the response to dopaminergic therapy in patients with PD for many years. The files of 47 patients who had been diagnosed with PD more than 13 years previously were reviewed. Mean age at disease onset was 47 9 years, and mean disease duration was 23.5 +/- 9.8 years. Levodopa treatment was initially effective in 95% of the patients but the response decreased with time. At the end of the follow-up period, end-stage disease, i.e. Hoehn and Yahr (H&Y) stage 5 was documented in 45% of the patients. In patients with response fluctuations H&Y stage was graded 5 in 53% of patients in the "off" period and in 27% in the "on" period. In patients without response fluctuations H&Y stage was graded 5 in 23% of patients. Two patients had stage 2 disease (minimal disability). In conclusion, PD has a chronic progressive course, although most patients do not reach end-stage disease. The effect of L-dopa treatment decreases over time, but is not lost completely. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:233 / 235
页数:3
相关论文
共 50 条
  • [31] Long-term results of ventrolateral thalamotomy for patients with Parkinson's disease
    Moriyama, E
    Beck, H
    Miyamoto, T
    NEUROLOGIA MEDICO-CHIRURGICA, 1999, 39 (05): : 350 - 356
  • [32] LONG-TERM EFFICACY OF INCOBOTULINUMTOXINA IN THE MANAGEMENT OF SIALORRHEA IN PARKINSON'S DISEASE
    Ianieri, Giancarlo
    Marvulli, Riccardo
    Gallo, Giulia
    TOXICON, 2018, 156 : S45 - S46
  • [33] Long-term retention rate of entacapone in the treatment of Parkinson's disease
    Keraenen, T.
    Tuhkasaari, M.
    Kuusisto, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (04) : E30 - E30
  • [34] Long-term retention rate of pramipexole in the treatment of Parkinson’s disease
    Tapani Keränen
    Mervi Tuhkasaari
    Hanna Kuusisto
    European Journal of Clinical Pharmacology, 2009, 65 : 955 - 956
  • [35] Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1
    Elm, Jordan J.
    MOVEMENT DISORDERS, 2012, 27 (12) : 1513 - 1521
  • [36] The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review
    Antonini, Angelo
    Odin, Per
    Pahwa, Rajesh
    Aldred, Jason
    Alobaidi, Ali
    Jalundhwala, Yash J.
    Kukreja, Pavnit
    Bergmann, Lars
    Inguva, Sushmitha
    Bao, Yanjun
    Chaudhuri, K. Ray
    ADVANCES IN THERAPY, 2021, 38 (06) : 2854 - 2890
  • [37] Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease
    Hauser, Robert A.
    Lew, Mark F.
    Hurtig, Howard I.
    Ondo, William G.
    Wojcieszek, Joanne
    Fitzer-Attas, Cheryl J.
    MOVEMENT DISORDERS, 2009, 24 (04) : 564 - 573
  • [38] Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study
    Hiorth, Ylva Hivand
    Alves, Guido
    Larsen, Jan Petter
    Schulz, Jorn
    Tysnes, Ole-Bjorn
    Pedersen, Kenn Freddy
    JOURNAL OF NEUROLOGY, 2017, 264 (02) : 364 - 372
  • [39] Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia
    Fabbri, Margherita
    Zibetti, Maurizio
    Calandra-Buonaura, Giovanna
    Contin, Manuela
    Sambati, Luisa
    Mohamed, Susan
    Romagnolo, Alberto
    Berchialla, Paola
    Imbalzano, Gabriele
    Giannini, Giulia
    Rizzone, Mario G.
    Artusi, Carlo Alberto
    Cortelli, Pietro
    Lopiano, Leonardo
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2020, 7 (08): : 930 - 939
  • [40] Selegiline as the primary treatment of Parkinson's disease - A long-term double-blind study
    Myllyla, VV
    Sotaniemi, KA
    Hakulinen, P
    MakiIkola, O
    Heinonen, EH
    ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (04): : 211 - 218